Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05552469
- Locations
- 🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT05548062
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT05544929
- Locations
- 🇺🇸
NYU School of Medicine, New York, New York, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05541159
Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 169
- Registration Number
- NCT05541328
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05541341
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, Brazil
Risk Perception in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4361
- Registration Number
- NCT05528666
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 222
- Registration Number
- NCT05526729
- Locations
- 🇯🇵
Novartis Investigative Site, Osaka, Japan
A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05524051
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸Duke Univ Medical Center Department of Medicine, Durham, North Carolina, United States
🇺🇸Univ of Texas Southwest Med Center Cardiovasc And Thoracic Surg, Dallas, Texas, United States
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1518
- Registration Number
- NCT05513014
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States